We tested the inhibition of MV-4–11 leukemia cells by TKIs sorafenib, sunitinib, and quizartinib, which have been clinically proven to be effective in FLT3-ITD-posiotive AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.